Question 1

What are the potential benefits of participating in this trial compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer clinical trial (NCT03186326). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from avelumab versus standard chemotherapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer clinical trial (NCT03186326). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer clinical trial (NCT03186326). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if my cancer progresses while I'm in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer clinical trial (NCT03186326). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any additional tests or procedures I would need to undergo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer clinical trial (NCT03186326). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial fit into my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer clinical trial (NCT03186326). Contact the study team or your healthcare provider for specific answers.

What this study is about